Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2023-08-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or comprehensive financial analysis but focuses on the update of the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2023-08-01 Chinese
亚宝药业集团股份有限公司2023年半年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as a '2023 Half-Year Performance Increase Announcement' and provides preliminary profit forecasts for the first half of 2023, including expected net profit and net profit excluding non-recurring items. It explicitly states that the forecasted results are unaudited and preliminary, and that the final accurate financial data will be disclosed in the formal 2023 half-year report. The document is short (1197 characters) and serves as an earnings forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and expectations, not the full interim report itself. H1 2023
2023-07-13 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. There is no financial statement or comprehensive report content, only an update on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2023-07-03 Chinese
亚宝药业集团股份有限公司关于回购股份比例达到1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the progress of its share repurchase program. It details the percentage of shares repurchased (1.30%), the total amount spent, and compliance with relevant regulations. The text focuses on the update of the company's buyback activity rather than presenting financial statements or detailed financial analysis. The document length is short (1014 characters), and it is clearly an update on share repurchase progress. Therefore, it fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back its own shares.
2023-06-29 Chinese
亚宝药业集团股份有限公司2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the implementation of the 2022 annual dividend distribution. It details the dividend per share, relevant dates for record, ex-dividend, and payment, the dividend distribution plan approved at the 2023 shareholders meeting, tax withholding policies, and instructions for shareholders. The document is focused on dividend amount and payment details rather than presenting financial statements or comprehensive financial performance. It is not a full annual report or earnings release but a specific announcement about dividend distribution. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is 2616 characters, which is consistent with a detailed dividend announcement rather than a full report.
2023-06-13 Chinese
北京市中勤律师事务所关于亚宝药业差异化分红事项法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's differentiated dividend distribution matter. It discusses the legal basis, the dividend scheme, calculation methods, and concludes on the compliance of the dividend distribution with relevant laws and regulations. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a specific corporate action (differentiated dividend). It does not contain financial statements or management discussion but is a legal advisory document. Therefore, it does not fit into categories like 10-K, IR, ER, or MDA. It is also not an announcement of voting results or a proxy statement. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not neatly fit into other categories, including legal opinions related to corporate actions.
2023-06-13 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.